Vasodilators Market Expected to Surpass USD $8.86 Billion by 2030, Expanding at 5.5% CAGR

 The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided.

How Is the Vasodilators Market Expected to Expand in Terms of Size and Growth?
The vasodilators market size has grown strongly in recent years. It will grow from $6.76 billion in 2025 to $7.16 billion in 2026 at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to increasing cases of hypertension, established clinical use of nitrates, growth in hospital infrastructure, rising incidence of heart failure, widespread availability of oral vasodilators.

The vasodilators market size is expected to see strong growth in the next few years. It will grow to $8.86 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to aging global population, rising burden of lifestyle-related diseases, expansion of specialty cardiac centers, increased focus on early diagnosis, growing access to cardiovascular medications. Major trends in the forecast period include rising prevalence of cardiovascular diseases, growing use of combination drug therapies, increased adoption of generic vasodilators, expansion of hospital-based cardiovascular care, higher demand for long-term hypertension management.

Claim your free report sample now:
https://www.thebusinessresearchcompany.com/report/vasodilators-global-market-report

What Are the Most Significant Drivers Affecting the Vasodilators Market Expansion?
The rising prevalence of cardiovascular diseases is expected to propel the growth of the vasodilators market going forward. Cardiovascular diseases refer to a group of disorders affecting the heart and blood vessels, such as coronary artery disease, heart failure, and stroke. The increasing prevalence of cardiovascular diseases is driven by rising obesity rates, which continue to escalate due to poor diet quality and sedentary lifestyles. The vasodilators market supports the management of cardiovascular diseases by relaxing blood vessels, lowering blood pressure, and improving overall blood circulation. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024, up 4.0% from 224.4 per 100,000 in 2023. Therefore, the rising prevalence of cardiovascular diseases is driving the growth of the vasodilators market.

What Segment Categories Define the Vasodilators Market Structure?
The vasodilators market covered in this report is segmented –

1) By Type: Arterial Dilators, Venous Dilators, Mixed Dilators
2) By Drugs: Nitroglycerin, Alprostadil, Minoxidil, Sorbitrate, Other Drugs
3) By Indication: Hypertension, Angina, Heart Failure, Other Indications
4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
5) By End User: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:
1) By Arterial Dilators: Calcium Channel Blockers, Nitric Oxide Donors, Potassium Channel Activators
2) By Venous Dilators: Nitrates, Nitrites, Phosphodiesterase Inhibitors (PDE5 Inhibitors)
3) By Mixed Dilators: Alpha-Adrenergic Antagonists, Angiotensin II Receptor Blockers (ARBs), ACE Inhibitors (Angiotensin-Converting Enzyme Inhibitors)

What Are the Significant Trends in the Vasodilators Market Across Regions?
Major companies operating in the vasodilators market are increasingly focusing on developing innovative solutions, such as inhaled soluble guanylate cyclase (sGC) activators, to improve pulmonary blood flow and manage cardiovascular conditions more effectively. Inhaled soluble guanylate cyclase (sGC) activators are drugs that, when inhaled, stimulate the sGC enzyme to relax blood vessels and improve blood flow, especially in the lungs. For instance, in September 2024, Roivant Sciences Ltd., a US-based biopharmaceutical and healthcare technology company, launched mosliciguat, a once-daily, inhaled sGC activator via a dry powder inhaler (DPI), developed by its subsidiary Pulmovant. Mosliciguat is formulated for lung-targeted delivery, activates sGC independent of heme and NO (which may preserve its function even under oxidative stress), and demonstrated in a Phase 1b “ATMOS” study mean‑max reductions in pulmonary vascular resistance (PVR) of up to ~38% in pulmonary hypertension patients. It was generally well tolerated, with low rates of adverse events, and its pharmacokinetic profile supports once-daily inhalation with a long half-life and limited systemic exposure. Pulmovant has initiated a global Phase 2 “PHocus” trial in ~120 patients with PH‑ILD to further assess its safety and efficacy.

Who Are the Prominent Players in theVasodilators Market?
Major companies operating in the vasodilators market are Pfizer Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AbbVie Inc., Abbott Laboratories, AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Novo Nordisk A/S, Astellas Pharma Inc., Amgen Inc., Gilead Sciences Inc., Biogen, Sun Pharmaceutical Industries Limited

Get the full vasodilators market report here:
https://www.thebusinessresearchcompany.com/report/vasodilators-global-market-report

How does the Vasodilators Market perform across different regions?
North America was the largest region in the vasodilators market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vasodilators market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: Global Market Research Reports & Consulting | The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: The Business Research Company | LinkedIn